863 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Bought by Integrated Investment Consultants LLC

Key Points

• Integrated Investment Consultants LLC has acquired 863 shares of United Therapeutics Corporation, valued at approximately $266,000, marking a new position for the firm in the biotechnology sector.
• Several institutional investors have recently increased their stakes in United Therapeutics, with 94.08% of the company's stock now owned by institutional holders.
• United Therapeutics reported a quarterly EPS of $6.63, surpassing analysts' expectations, with a revenue increase of 17.2% year-over-year, indicating strong market performance.

Integrated Investment Consultants LLC acquired a new position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 863 shares of the biotechnology company's stock, valued at approximately $266,000.

Several other institutional investors have also recently made changes to their positions in UTHR. Dunhill Financial LLC raised its stake in United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 50 shares during the period. Sound Income Strategies LLC bought a new stake in United Therapeutics during the 1st quarter worth approximately $49,000. State of Wyoming bought a new stake in United Therapeutics during the 4th quarter worth approximately $62,000. Curat Global LLC bought a new stake in shares of United Therapeutics during the 1st quarter valued at $63,000. Finally, Natixis bought a new stake in shares of United Therapeutics during the 4th quarter valued at $85,000. Institutional investors own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In related news, Director Nilda Mesa sold 645 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the transaction, the director owned 4,883 shares of the company's stock, valued at $1,416,021.17. This represents a 11.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total value of $3,079,560.00. Following the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $10,297,208.76. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 81,681 shares of company stock valued at $24,628,589 over the last 90 days. 10.30% of the stock is currently owned by insiders.

United Therapeutics Stock Performance

UTHR opened at $304.50 on Friday. The stock's 50 day moving average price is $300.01 and its 200-day moving average price is $315.85. The stock has a market cap of $13.74 billion, a price-to-earnings ratio of 12.15, a P/E/G ratio of 6.64 and a beta of 0.53. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The business's revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the prior year, the business posted $6.17 earnings per share. As a group, analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Cantor Fitzgerald began coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price objective on the stock. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Morgan Stanley decreased their target price on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. HC Wainwright reissued a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research note on Monday, May 5th. Finally, UBS Group decreased their target price on United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $383.08.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.